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Background: Cancer treatment-related lymphedema (CTRL) affects patients physically,
psychologically and emotionally, and remains a significant quality of life issue among
patients with cancer. Reliable methods to measure changes in lymphedema are required
for early detection, acute intensive treatment, and long-term management. Here, we
evaluated the use of bioimpedance analysis (BIA) as a tool to measure lymphedema
before and after treatment.
Patients and Methods: Patients with CTRL who were admitted to a secondary
university hospital between October 2017 and July 2018 for complex decongestive
therapy (CDT) were eligible for this prospective cohort study. Circumferential measure
(CM) and BIA were used to evaluate lymphedema at admission (initial) and before
discharge (follow-up, FU). Volume was calculated from the CM using the truncated cone
formula. The inter-limb ratios (ILRs) of the circumference, volume, and impedance were
also calculated as the unaffected limb to affected limb. Each parameter before and after
treatment and correlations between parameters also were analyzed.
Results: A total of 29 patients (12 upper- and 17 lower-extremity CTRL) completed
were included in this analysis. Absolute value and the ILRs of circumference, volume
or impedance, and extracellular water/total body water (ECW/TBW) were significantly
improved at FU (p < 0.01, p < 0.05). The initial and FU absolute values, ILRs,
ECW/TBW correlated significantly with each other (p < 0.01, p < 0.05). The cutoff
values of ECW/TBW for moderate and severe degree of CTRL were 0.3855 and 0.3955,
respectively. The changes of ILRs between initial and FU assessments were significantly
different among three groups according to lymphedema severity (p < 0.01, p < 0.05).
Conclusions: BIA data correlates significantly with clinical measurement, and therefore
can be a practical tool in monitoring outcome measure after lymphedema treatment. In
addition, BIA is more sensitive to subtle changes in lymphedema, and therefore can be
useful for the long-term maintenance of lymphedema.
Keywords: cancer treatment-related lymphedema, bioimpedance analysis, complex decongestive therapy, breast
cancer, gynecologic cancer
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INTRODUCTION
As survival among patients with breast and gynecological cancers
has improved over the past few decades (1–3), greater emphasis
has been directed toward long-term cancer treatment sequelae,
such as lymphedema. Cancer treatment-related lymphedema
(CTRL) develops due to the disturbance of lymphatic flow
by surgery and/or radiation therapy. Although the reported
incidence varies across studies, 13–42% of patients with breast
cancer and 20–50% of patients with gynecologic cancer are
reported to suffer from lymphedema (4–8). The development
of lymphedema results in physical impairments including
compromised function, diminished strength, fatigue, and pain in
the affected limb as well as negative psychological and emotional
effects, including anxiety, frustration, sadness, anger, fear, and
decreased self-confidence. Thus, due to its significant impact on
quality of life (9–11), early detection and intensive treatment of
CTRL is needed.
Several methods to evaluate lymphedema are currently used.
A measuring tape is used for circumferential measurement (CM)
of the affected limb (which in turn is used to calculate the
volume via the truncated cone formula). The CM is widely used
to evaluate lymphedema because it is cost-effective and easy to
implement (12, 13). There are major concerns with CM, however,
including the variance in inter-rater and intra-rater reliability
and the difficulty in detecting early lymphedema changes.
Imaging methods, such as lymphoscintigraphy and magnetic
resonance (MR) lymphangiography, have several drawbacks,
including pain, cost, and time. Ultrasonography also has several
disadvantages: it can detect structural but not physiological
changes, it is costly, there is no standardized evaluation method,
and the site of evaluation is difficult to determine.
Bioimpedance analysis (BIA) has been introduced as a new
method for evaluating lymphedema in the early 1990’s (14).
BIA is easy to implement and enables indirect quantification of
extracellular fluid via the response of the body to an applied
electrical current. The examiner does not need special skills to
conduct BIA, and the test can be conducted in 3–5min. Several
studies have reported that BIA is correlated with measurements
from CM and ultrasonography, and that BIA can be used for
early diagnosis of lymphedema (15–18). Here, we extend the
findings of these prior studies to validate the use of BIA in
the assessment of lymphedema after phase one of complex
decongestive treatment (CDT). In contrast to previous studies,
in which the test results were compared at one time point, here
we conduct serial comparisons to determine the utility of BIA
in evaluating lymphedema longitudinally, including as a reliable
measure of treatment outcome.
METHODS
Participants
This was a prospective cohort study of 54 patients with CTRL
who were admitted to the secondary university hospital for short-
term (i.e., 2–6 weeks) treatment of lymphedema betweenOctober
2017 and July 2018.
Lymphedema was diagnosed by clinical and
lymphoscintigraphic evaluation. Lymphedema was confirmed
when the circumference of the affected limb exhibited a 5%
change in volume or was <2 cm at any site compared with the
unaffected limb at two consecutive assessments. Lymphedema
was diagnosed if any subjective symptoms and abnormalities on
the lymphoscintigraphy were present at the same time, regardless
of the circumference or volume criteria. The patient’s subjective
symptoms, including swelling, heaviness, fullness, and vague
pain were considered in the clinical diagnosis. A diagnosis via
lymphoscintigraphy included decreased clearance of injection
site, asymmetric visualization of lymphatic or collateral vessels,
presence of dermal back flow, and reduced or no uptake of
radiotracer on lymph nodes.
Among eligible patients, only those who agreed to participate
in the study and who underwent CDT were included. Patients
were excluded for: (1) bilateral lymphedema, (2) history of
orthopedic surgery on the affected limb prior to the development
of lymphedema, (3) recurrent cancer, (4) vascular disease, and (5)
systemic disease associated with limb edema.
A total of 29 patients with unilateral lymphedema (12 upper-
extremity and 17 lower-extremity) were included in the analysis.
Of those excluded from the analysis, 6 patients had bilateral
lymphedema; 3 had a combination of exclusionary medical
conditions, such as chronic kidney disease, heart disease, and
stroke; 3 had vascular disease; 2 had recurrent cancer; and
1 had a previous knee surgery on the affected limb. Ten
patients who did not agree to participate in the study also were
excluded (Figure 1).
Complex Decongestive Therapy
On the day of admission, patients were informed about the
purpose and procedures for CDT. The short-term reduction
phase of CDT consisted of multi-layered compression bandaging
(MLCB), manual lymphatic drainage (MLD), remedial exercise,
and skin care which started the day after hospitalization.
One physical therapist applied the MLCB to the affected
limb and it was maintained for more than 22 h a day except
during the MLD and to clean the limb. Each morning, one
physiatrist unwrapped the MLCB, checked the skin condition
and measured the circumference of the unaffected and affected
limbs. Subsequently, the physical therapist performed morning
MLD and immediately after MLCB was applied to the affected
limb. Remedial exercise, including stretching, aerobic exercise,
and resistance exercise were performed under the instruction of
the therapist for 90min per day. Prior to afternoon MLD, the
therapist unwrapped MLCB again, and the skin condition was
evaluated. After washing the body, the physical therapist applied
MLCB which was kept until the next morning.
Nutrition management was also conducted in consultation
with nutritionists. One physical therapist who specialized in
lymphedema treatment performed MLD twice per day for
30min. CDT was terminated when there was no change in the
CM for 3 or more consecutive days.
Lymphedema Evaluation
Lymphedema was evaluated via both BIA and CM at the initial
admission (initial) and before discharge (follow-up, FU). For
upper extremity measurements, the circumference was measured
at both 10 cm above and below the elbow crease, and wrist
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FIGURE 1 | Diagram of participants. LE, lymphedema.
while the patient was sitting with the elbow extended. For lower
extremity measurements, the circumference was measured at
both 10 cm, 20 cm above, and 10 cm below the lower border of
the patella and ankle while the patient was supine with the knee
extended. All measurements were performed three times by one
physiatrist, and the average value was recorded. The sum of arm
or leg circumference was calculated by summing the perimeters
measured at the above-mentioned positions.
BIA was measured via a multi-frequency impedance
plethysmograph body composition analyzer (Inbody720,
Biospace, Seoul, Korea) by one experienced medical laboratory
technician. Impedance was measured at a frequency of 1 kHz in
both the affected and unaffected limb which reflect the lymph
volumes. The ratio of extracellular water (ECW) to total body
water (TBW) which represent status of ECF (extracellular fluid)
and edema was obtained. It categorized as follows: constant
state-0.38, mild overhydrated state-0.390–0.399, and moderate
to severe overhydrated state ≥0.400) (19).
The inter-limb ratios (ILRs) of CM or impedance were
calculated based on below formula at the beginning and the
end of hospitalization. These initial and FU results of ILR
were compared.
Inter − limb ratio =
affected limb measurement ÷ unaffected limb measurement
The limb volume was derived from the CM using the truncated
cone formula. The relative percentage increase of volume
(%RVI) of affected limb compared to unaffected limb was
defined as [(affected arm or leg volume/unaffected arm or leg
volume)−1]∗100. Patients were classified by their initial %RVI
as mild (<15%), moderate (15–36%), or severe (>37%) (20).
According to lymphedema severity, the effects of CDT were
compared. The cutoff values of ECW/TBW were obtained using
receiver-operating characteristic (ROC) curve for detecting mild
and severe degree of CTRL.
This study was approved and conducted in accordance with
the recommendations of the institutional review board (IRB)
of our university hospital (approval number: 2017-02-024).
Informed consent was obtained from all participants prior to
conducting any measurements.
Statistical Analysis
Simple descriptive statistics and frequency analysis were used to
characterize the samples and the distribution of variables. Data
are presented as median (interquartile range) for continuous
variables and all parameters of clinical outcome and BIA. The
initial and FU circumference, and volume were compared by
Wilcoxon signed-rank test. The absolute values of CM and
volume between the affected and the unaffected side were also
compared by Wilcoxon signed-rank test. For comparisons of
changes in ILR of circumference, volume, and impedance among
three severity groups during short-term in-hospital stay, one-way
analysis of variance (ANOVA) test was used. Repeated measures
ANOVA was used for both the intra-group and intergroup
comparison of the CDT effects depending on lymphedema
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TABLE 1 | Characteristics of patients with lymphedema.
Parameters
Age (years) 54.0 (47.5–61.0)
Treatment method
Surgery 29 (100)
CTx 6 (20.7)
RTx 0
CTx+RTx 18 (62.1)
No CTx or RTx 5 (17.2)
Upper/Lower affected limb 12/17 (41.4/58.6)
Right/Left affected limb 13/16 (44.8/55.2)
Time to CDT (months) 8.0 (5.5–14.0)
Upper extremity 7.0 (2.8–13.3)
Lower extremity 8.0 (6.0–16.0)
Duration of CDT (days) 9.0 (9.0–15.0)
Mild (n = 13) 9.0 (9.0–15.0)
Moderate (n = 12) 11.5 (8.0–12.5)
Severe (n = 4) 19.5 (11.3–24.0)
Values are reported as the median (interquartile range) or numbers (%). CTx,
Chemotherapy; RTx, Radiotherapy; CDT, complex decongestive therapy; n, numbers.
severity. For comparison of values among three groups at
each time, one-way ANOVA and the Bonferroni post-hoc test
were used.
The cutoff values were obtained using ROC curves for
calculated ECW/TBW of mild and severe CTRL. Sensitivity and
specificity were calculated with cutoff values of the BIA.
Spearman’s correlation coefficients were calculated to
investigate associations among parameters. Statistical analysis
was performed using standard statistical software (SPSS version
21.1 forWindows, SPSS, Inc., Chicago, IL, USA). The significance
level was set at 0.05 for all comparisons.
RESULTS
A total of 29 patients, 12 of whom had CTRL in an upper
extremity and 17 of whom had CTRL in a lower extremity, were
included in this analysis. All patients had undergone previous
surgical treatment for breast or gynecological cancer. Themedian
time from the onset of lymphedema to CDT was 8.0 months.
The median duration of CDT was 9 days (9.0 days for mild,
11.5 days for moderate, and 19.5 days for severe degree of
CTRL; Table 1).
At initial assessment, the circumference and volume were
significantly different between the affected and unaffected
limb in both upper and lower extremities (Table 2, p <
0.05). There was a significant improvement in the absolute
value of circumference, volume, and ECW/TBW and ILR of
circumference, volume, impedance after CDT (Table 2, Figure 2,
p < 0.01, p < 0.05).
Initial absolute value of circumference of affected limb was
significantly correlated with initial impedance in affected (r =
−0.651∗∗) and unaffected (r = −0.841∗∗) limb, absolute value
of circumference in unaffected limb (r = 0.953∗∗) and follow up
TABLE 2 | Change in evaluation parameters after complex decongestive therapy.
Initial Follow up P value
Lymphedema severity
Mild/moderate/severe 12/13/4 22/7/0
Weight (kg) 62.5 (58.3–67.8) 62.8 (56.8–68.5) 0.057
BMI (kg/m2) 25.0 (23.5–28.6) 25.7 (23.2–28.7) 0.016*
Body fat (%) 34.4 (28.8–40.2) 34.2 (28.9–40.9) 0.572
Body fat (kg) 23.1 (16.7–30.00) 22.7 (17.6–28.2) 0.909
ECW/TBW 0.39 (0.386–0.397) 0.39 (0.385–0.395) 0.009**
Sum of circumference (cm)
Upper extremity
Affected limb 90.1 (85.9–99.3) 87.0 (81.6–93.4) 0.002**
Unaffected limb 85.5 (81.3–87.4) 83.7 (80.1–86.5) 0.015*
p value 0.002
††
0.002
††
Lower extremity
Affected limb 158.0 (132.0–169.8) 152.5 (144.5–157.7) 0.005**
Unaffected limb 146.5 (123.5–153.8) 142.0 (138.5–150.8) 0.016*
p value <0.001
††
<0.001
††
Volume (L)
Upper extremity
Affected limb 11.4 (10.4–13.7) 10.8 (9.6–12.2) 0.002**
Unaffected limb 9.8 (9.1–10.8) 9.8 (9.0–10.5) 0.041*
p value 0.002
††
0.002
††
Lower extremity
Affected limb 49.1 (37.3–56.9) 44.8 (33.6–44.8) <0.001**‘
Unaffected limb 40.8 (33.5–46.9) 39.0 (31.1–44.0) 0.001**
p value <0.001
††
<0.001
††
ILR (S)
Upper extremity 0.92 (0.90–0.96) 0.96 (0.93–0.98) 0.003**
Lower extremity 0.93 (0.91–0.95) 0.97 (0.93–0.97) 0.001**
ILR (V)
Upper extremity 0.84 (0.78–0. 89) 0.91 (0.85–0.93) 0.002**
Lower extremity 0.89 (0.82–0.91) 0.93 (0.87–0.97) 0.001**
ILR (I)
Upper extremity 1.45 (1.11–1.58) 1.3 (1.08–1.45) 0.008**
Lower extremity 1.35 (1.16–1.56) 1.16 (1.10–1.29) 0.001**
Values are reported as the median (interquartile range). *p < 0.05, **p < 0.01, compared
to the initial assessment.
††
p < 0.01, compared to the unaffected limb. BMI, body mass
index; ILR, inter-limb ratio; S, Sum of circumference; V, Volume; I, Impedance; ECW,
extracellular water; TBW, total body water.
(FU) absolute value of circumference in affected (r = 0.971∗∗)
and unaffected (r = 0.944∗∗) limb and impedance in affected (r
= 0.593∗∗) and unaffected (r = −0.778∗∗). Initial ILR (I) was
significantly correlated with initial ECW/TBW (r = 0.649∗∗),
absolute value of impedance of affected limb (r = −0.745∗∗) and
ILR (S) (r =−0.820) and FU ECW/TBW (r = 0.591∗∗), absolute
value of impedance of affected (r = −0.766∗∗) and unaffected
(r = −0.387∗) limb and ILR (S) (r = −0.778) and ILR (I) (r =
0.896∗∗) (Table 3). It is consistent with the findings of previous
studies (15, 21).
Initial and FU ECW/TBW and ILRs for circumference, and
impedance revealed significant strong correlations with each
other (Table 3, r > 0.7, p < 0.01).
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FIGURE 2 | Improvement of inter-limb ratio of sum of circumference and impedance after complex decongestive therapy. **p < 0.01. ILR, inter-limb ratio; S, Sum of
circumference; I, Impedance.
TABLE 3 | Correlations between initial and follow-up inter-limb ratios of
circumference, impedance, and extracellular fluid status.
Initial Follow up
ILR (S) ILR (I) ECW/TBW ILR (S) ILR (I) ECW/TBW
INITIAL
ILR (S) 1 −0.820** −0.622** 0.826** −0.833** −0.529**
ILR (I) −0.820** 1 0.649** −0.778** 0.896** 0.591**
ECW/TBW −0.622** 0.649** 1 −0.508** 0.512** 0.798**
FOLLOW-UP
IRL (S) 0.826** −0.778** −0.508** 1 −0.816** −0.461*
IRL (I) −0.833** 0.896** 0.512** −0.816** 1 0.499**
ECW/TBW −0.529** 0.591** 0.798** −0.461* 0.499** 1
*p < 0.05, **p < 0.01 by Spearman’s correlation. ILR, inter-limb ratio (unaffected
side/affected side); S, Sum of circumference; I, Impedance; ECW, extracellular water;
TBW, total body water.
When patients were divided according to the severity
of their CTRL volume, nine patients (75.0%) among 12
patients with initially moderate degree of CTRL improved to
mild degree after CDT. Similarly, all four patients originally
classified as severe degree of CTRL were improved to
moderate degree of CTRL after CDT. Finally, 22 patients were
classified as mild degree and 7 patients as moderate degree
after CDT.
The initial values of relative percentage increase in sum
of circumference (%RSI), volume (%RVI), impedance (%RII),
inter-limb ratios of circumference, volume, and impedance
(p < 0.001∗∗) and ECW/TBW (p = 0.004∗∗) revealed
significant inter-group difference among three severity groups.
Also, significant improvements in the %RSI, %RVI, %RII,
ECW/TBW, and absolute values of ILRs of circumference
and impedance were induced by CDT (Table 4). Changes in
ILR of sum of circumference (p < 0.001∗∗), volume (p =
0.002∗∗), and impedance (p = 0.046∗) between initial and FU
evaluation after CDT according to the severity of lymphedema
was significantly different among three groups according to
severity (Figure 3).
Initial and FU ECW/TBW showed moderate to high
correlation with initial and FU %RSI, %RVI, and %RII (Table 5).
The cutoff value for ECW/TBWwhich distinguishmild degree
of CTRL from other degrees of CTRL was 0.3885. The area under
the curve (AUC) was 0.800 (p = 0.006∗∗) and the sensitivity and
specificity were 87.5 and 69.2%, respectively. The cutoff value for
ECW/TBW which distinguish severe degree of CTRL from other
degrees of CTRL was 0.3955. The area under the curve (AUC)
was 0.820 (p = 0.043∗) and the sensitivity and specificity were
75.0 and 76.0%, respectively.
DISCUSSION
Lymphedema is composed of accumulated protein, fluid, fibrotic,
and fatty tissues in the extravascular interstitium which is
influenced by stage of CTRL. BIA can differentiate ECF from
total limb volume and is useful for early diagnosis and assessing
severity of lymphedema (17, 22–25).
Body composition and ECF status should be carefully
considered for determining the CDT effects on CTRL. However,
to the best of our knowledge, there are few studies to report
the feasibility of BIA as a tool of serial evaluation for treatment
outcomes in patients with lymphedema.
In this study, CDT induced significant improvement of
absolute value or ILR of circumference, calculated volume,
impedance, and ECW/TBW in CTRL (Tables 2, 4). In addition,
we identified a strong relationship between the ILR of impedance
of BIA, the ILRs of circumference and ECF status at the
initial and FU evaluation, respectively (Table 3). Furthermore,
initial and FU ECF status and a relative percentage increase of
circumference, volume, and impedance significantly correlated
with each other (Table 5). Therefore, it suggests that BIA may be
a useful tool to monitor not only changes in circumference, but
also changes in body composition in CTRL therapy.
When patients were grouped by severity, there were
significant differences in ECW/TBW, %RSI, %RVI, %RII,
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TABLE 4 | Changes of parameters of circumference, volume, impedance, and extracellular fluid status after complex decongestive therapy according to the severity
of lymphedema.
Initial Follow up Time effect
p value
Time*group effect
p value
%RSI <0.001** <0.001**
Mild (n = 13) 4.9 (2.6–6.1) 2.4 (1.6–3.2) <0.001§§
Moderate (n = 12) 9.2 (7.9–10.1) 4.9 (3.6–6.5) <0.001
††
Severe (n = 4) 19.6 (17.4–21.0) 10.4 (9.4–11.2) <0.001
††
<0.001§§
%RVI <0.001** <0.001**
Mild (n = 13) 10.7 (7.1–12.1) 4.4 (2.5–6.9) <0.001§§
Moderate (n = 12) 20.0 (18.8–24.8) 12.1 (9.5–16.5) <0.001
††
Severe (n = 4) 45.8 (40.2–68.1) 28.0 (23.2–32.1) <0.001
††
<0.001§§
%RII <0.001** 0.05
Mild (n = 13) 11.4 (7.3–33.7) 8.6 (6.4–16.3) 0.003§§
Moderate (n = 12) 44.7 (32.7–58.0) 29.9 (15.4–44.2) 0.003
††
Severe (n = 4) 81.6 (59.2–104.3) 64.4 (39.7–66.3) <0.001
††
0.019§
ECW/TBW 0.043* 0.364
Mild (n = 13) 0.39 (0.38–0.39) 0.39 (0.38–0.39) 0.177
Moderate (n = 12) 0.40 (0.39–0.40) 0.39 (0.38–0.40) 0.177
Severe (n = 4) 0.41 (0.39–0.42) 0.40 (0.39–0.41) 0.007
††
0.167
ILR (S) <0.001** <0.001**
Mild (n = 13) 0.95 (0.94–0.97) 0.98 (0.97–0.98) <0.001§§
Moderate (n = 12) 0.91 (0.91–0.93) 0.95 (0.93–0.97) <0.001
††
Severe (n = 4) 0.84 (0.83–0.85) 0.91 (0.90–0.92) <0.001
††
<0.001§§
ILR (V) <0.001** <0.001**
Mild (n = 13) 0.90 (0.89–0.93) 0.96 (0.93–0.98) <0.001§§
Moderate (n = 12) 0.83 (0.80–0.84) 0.89 (0.86–0.91) <0.001
††
Severe (n = 4) 0.69 (0.60–0.71) 0.78 (0.75–0.81) <0.001
††
<0.001§§
ILR (I) <0.001** 0.046*
Mild (n = 13) 1.1 (1.08–1.34) 1.09 (1.07–1.16) 0.003§§
Moderate (n = 12) 1.45 (1.33–1.58) 1.30 (1.16–1.45) 0.003
††
Severe (n = 4) 1.82 (1.59–2.04) 1.64 (1.39–1.66) <0.001
††
0.021§
Values are reported as the median (interquartile range). *p < 0.05, **p < 0.01, compared to patients among three groups.
††
p < 0.01, compared to patients with mild lymphedema by
the Bonferroni post-hoc test. §p < 0.05, §§p < 0.01, compared to patients with moderate lymphedema the Bonferroni post-hoc test. %RSI, relative percentage sum of circumference
increase %RVI, relative percentage volume increase; %RII, relative percentage impedance increase; ILR, inter-limb ratio; S, Sum of circumference; I, Impedance.
ILR of circumference, volume, and impedance according to
severity at initial assessment. Also, there were significant
intergroup differences according to time, except for ECW/TBW.
ECW/TBW were significantly improved in CTRL, regardless
of severity (Table 4). Furthermore, 75.0% of patients classified
with moderate CTRL improved to mild CTRL after CDT, and
100% of patients originally classified with severe CTRL improved
to moderate CTRL after CDT. Although patients with severe
CTRL underwent a longer duration of treatment (by ∼1 week)
than patients with mild or moderate CTRL (Table 1), it suggests
that patients with severe lymphedema might expect favorable
outcomes with short-term intensive CDT.
Interestingly, parameters in unaffected limb as well as affected
limb showed changes after CDT. As high pre-treatment BMI
(>30) is a well-established risk factor for lymphedema (26,
27), our CDT program included weight management during
CDT. However, there were no significant changes of weight or
body fat contents after CDT (Table 2), despite BMI is changed
significantly at FU (Table 2). Because the number of patients
participated in the current study was relatively small and the
BMI of all patients ranged <30 and the duration of treatment
was as short as 12 days, the effect of our program on weight
management remains uncertain to draw conclusions. Thus, the
improvement of circumference, volume, and impedance of the
unaffected limb as well as the affected limb at FU is thought
to be related to the improvement of edema status which is
represented by ECW/TBW (Tables 2, 5). Further research should
be needed to determine whether reducing BMI affects treatment
outcomes, especially because the management of lymphedema is
a lifelong issue.
Previous studies have focused primarily on BIA as a diagnostic
tool for lymphedema, with several studies highlighting its utility
for early diagnosis of lymphedema (17, 22, 23). One study
reported that BIA was associated with nearly 100% sensitivity
and specificity for early detection of lymphedema (17). In
contrast, another study reported the sensitivity and specificity
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of bioimpedance compared to volume displacement as 75 and
93%, respectively (28). These studies indicate that clinical and
laboratory methods are needed in addition to BIA to accurately
diagnosis lymphedema. While these studies focused on upper
limb lymphedema, several studies on gynecological cancer
employed BIA for lower limb lymphedema (29). However, the
utility of BIA in these studies were to establish an early detection
of lymphedema, perioperative fluid imbalance, or postoperative
complications. Therefore, additional studies are needed to test
the sensitivity and specificity of BIA for evaluation of CDT effect
on lower extremity lymphedema.
Notably, the cutoff value of ECW/TBW were calculated
as 0.3885 (moderate) and 0.3955 (severe) which were slightly
lower, compared with the category of simple edema (19).
It might be resulted from the composition of lymphedema
contents. Lymphedema is a chronic and progressive condition
FIGURE 3 | Change of inter-limb ratio of sum of circumference, volume,
impedance between initial and follow up evaluation after complex decongestive
therapy according to the severity of lymphedema. *p < 0.05, **p < 0.01. ILR,
inter-limb ratio; S, Sum of circumference; V, Volume; I, Impedance.
that requires constant management over the lifetime (30, 31).
Patients with lymphedema who have completed the short-
term reduction phase of CDT enter the long-term maintenance
phase of CDT. Our results demonstrated the possibility of
BIA parameters as monitoring indicator in both upper and
lower limbs lymphedema. The outcome from the short-term
reduction phase becomes the patient’s new baseline. When
a change from this baseline occurs during the long-term
maintenance phase, then the patient must return to the
reduction phase of CDT. It is important to detect small changes
as soon as possible, because small changes require shorter
durations of treatment, and early detection of minute changes
in lymphedema are associated with more favorable long-term
outcomes and improved quality of life and function (9, 10,
32). Circumference and volume measurement are commonly
used to monitor lymphedema during the maintenance phase
because they are easy and cost effective to conduct. But volume
measurement needs specific equipment such as perometer or
water displacement volumetry. BIA also is a non-invasive
measure and is convenient for both the physician and the
patients. Reference values for healthy populations and standards
for diagnosis of lymphedema have been established for BIA
(33). However, considering individual variability especially
noted for obese individuals (34), the patient’s longitudinal
value after CDT can be used as a reference during long-
term maintenance.
This study has several limitations. A relatively small number of
patients were included in the analysis. One advantage, however,
is that our cohort included patients with lymphedema in both
the upper and lower extremities. In this study, we assessed
BIA in the evaluation of improvements before and after the
reduction phase of CDT. Long-term studies should evaluate
whether BIA is a reliable tool of continuous monitoring during
the maintenance phase of CDT. The number of circumference
measurements performed on each limb is too few to calculate
accurate volume using truncated cone formula. While this study
primarily focused on trends in segmental volume change, the
TABLE 5 | Correlations of initial and follow-up ECW/TBW with a relative percentage increase of circumference, volume, and impedance.
Initial Follow up
ECW/TBW %RSI %RVI %RII ECW/TBW %RSI %RVI %RII
INITIAL
ECW/TBW 1 0.633** 0.580** 0.650** 0.798** 0.534** 0.526** 0.529**
%RSI 0.633** 1 0.902** 0.835** 0.522** 0.841** 0.753** 0.856**
%RVI 0.580** 0.902** 1 0.783** 0.492** 0.770** 0.867** 0.768**
%RII 0.650** 0.835** 0.783** 1 0.590** 0.766** 0.705** 0.898**
FOLLOW UP
ECW/TBW 0.798** 0.522** 0.492** 0.590** 1 0.465** 0.522** 0.508**
%RSI 0.534** 0.841** 0.770** 0.766** 0.465* 1 0.845** 0.791**
%RVI 0.526** 0.753** 0.867** 0.705** 0.522** 0.845** 1 0.699**
%RII 0.529** 0.856** 0.768** 0.898** 0.508** 0.791** 0.699** 1
*p < 0.05, **p < 0.01 by Spearman’s correlation. ECW, extracellular water; TBW, total body water; %RSI, relative percentage increase of sum of circumference; %RVI, relative percentage
increase of volume; %RII, relative percentage increase of impedance.
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data in BIA reflects whole arm or leg. Therefore, future study
is desirable to measure the circumference of more areas or
use segmental perometry for accurate volume estimation. In
addition, due to small numbers of participants, we couldn’t
perform subgroup analysis according to lymphedema stages.
Because BIA results can vary depending on the condition of
the skin, the clinical value of BIA might be emphasized on the
higher stages. Thus, further research is needed to understand
whether the interpretation of BIA values depend on not only
the degree of lymphedema but also the stages of lymphedema,
especially among patients with terminal stage of lymphedema
with irreversible skin changes.
In conclusion, BIA is practical to measure lymphedema
treatment outcomes. BIA is more sensitive for detecting subtle
changes after CDT than CM or volume measurement in relation
to ECF status. Therefore, it would be useful for the long-
term maintenance care of lymphedema as well. Despite our
small sample size, estimated improvement in BIA of patients
with mild, moderate, and severe lymphedema was ∼0.02, 0.03,
and 0.07 in inter-limb ratio of circumference sum and −0.05,
−0.13, −0.3 in inter-limb ratio of impedance, respectively, after
treatment. Based on the results of this study, it is necessary to
determine whether BIA can be used for long-term monitoring
of lymphedema, which would facilitate long-term management
of this condition and ultimately improve the quality of life of
patients with lymphedema.
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